Clinical and dopaminergic imaging characteristics of the "FARPRESTO" cohort of trial-ready idiopathic REM sleep behavior patients.
Dario ArnaldiPietro MattioliMatteo PardiniSilvia MorbelliElena CaprigliaAnnalisa RubinoValter RustioniMichele TerzaghiElisa CasagliaAlessandra SerraMichela FigorilliClaudio LiguoriMariana FernandesFabio PlacidiLuca BaldelliFederica ProviniLuigi Ferini-StrambiSara MarelliGiuseppe PlazziElena AntelmiValerio BrunettiEnrica BonanniMonica Puligheddunull nullPublished in: European journal of neurology (2023)
Clinical data (older age, motor and cognitive impairment, constipation, urinary and sexual disfunction, depression) predicted phenoconversion in this multicenter longitudinal observational study. A standardized visual approach for semi-quantification of DaT-SPECT is proposed as practical risk factor for phenoconversion in iRBD patients. To note, non-converted and newly diagnosed iRBD patients, who represent a trial-ready cohort for upcoming disease-modification trials, are currently being enrolled and followed in the FARPRESTO study. New data are expected to allow better risk characterization.
Keyphrases
- newly diagnosed
- end stage renal disease
- chronic kidney disease
- ejection fraction
- cognitive impairment
- clinical trial
- prognostic factors
- peritoneal dialysis
- physical activity
- randomized controlled trial
- high resolution
- depressive symptoms
- machine learning
- cross sectional
- patient reported outcomes
- phase ii
- phase iii
- artificial intelligence
- patient reported
- community dwelling